AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02220452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: absence of music listening during anesthesia
Description: In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
Study NCT02977832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Odyliresin
Description: Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
Study NCT02977832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: 10Mg Oral Tablet, Extended Release
Study NCT02502526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centurion® Vision System, 45° Balanced Tip
Study NCT02502526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centurion® Vision System, 45° MFK Tip
Study NCT02502526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lnfiniti® Vision System, 45° MFK Tip
Study NCT02502526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTREPID® Ultra infusion sleeve
Study NCT02502526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTREPID® Ultra infusion sleeve
Study NCT02502526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra infusion sleeve
Study NCT04455204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum asymmetteric dimethyl arginine
Description: Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
Study NCT04455204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid profiles
Description: serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
Study NCT04455204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vaspin
Description: vaspin concentrations will be assayed using commercially available ELISA kits
Study NCT04455204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum resistin
Description: resistin concentrations will be assayed using commercially available ELISA kits
Study NCT01957332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular imaging
Description: On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
Study NCT01957332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular imaging
Description: All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
Study NCT03783416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib (NINLARO®) capsules / Matching placebo capsules
Description: Participants will be treated for a maximum of 24 months
Study NCT03783416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixazomib (NINLARO®) capsules / Matching placebo capsules
Description: Participants will be treated for a maximum of 24 months
Study NCT00885313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA250
Description: DHA 250 mg/kg/d
Study NCT00885313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA500
Description: DHA 500 mg/kg/d
Study NCT00885313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo
Study NCT00885313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
Study NCT00885313 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
Study NCT04621435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 labelled (68Ga-) FAP-2286
Description: The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
Study NCT04621435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) imaging
Description: Participants will be scanned for approximately 30 to 45 minutes
Study NCT04621435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled (64Cu-) FAP-2286
Description: The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
Study NCT00819546 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RAD001
Description: Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
Study NCT00819546 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PKC412
Description: 50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
Study NCT03910855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
Study NCT03910855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
Study NCT03178149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7317
Description: subretinal injection
Study NCT03178149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT03777878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: 20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
Study NCT03178149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: oral
Study NCT03178149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: oral
Study NCT03178149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: oral
Study NCT00368745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
Study NCT00368745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
Study NCT01485731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
Study NCT01485731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
Study NCT01485731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic External Beam Radiation Therapy
Description: Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
Study NCT01485731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Sampling
Description: Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Biopsy
Description: Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Examination
Description: Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pap Smear
Description: Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiogram
Description: Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy
Description: Optional. Pre-Treatment
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoscopy
Description: Optional. Pre-Treatment
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Ultrasound
Description: Optional. Pre-Treatment
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
Study NCT01485731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Body PET/CT Scan
Description: In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
Study NCT01147887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug combination/ 26489112
Description: On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
Study NCT04204694 — intervention group
Intervention type: OTHER
Intervention: 3-time blood sampling for septic shock patients
Description: 15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
Study NCT04204694 — intervention group
Intervention type: OTHER
Intervention: Only one blood sampling for controls patients
Description: 15 mL blood are sampled from a blood donation
Study NCT04310982 — intervention group
Intervention type: DEVICE
Intervention: The G-Walk sensor system (G-Walk)
Description: The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
Study NCT03294460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Oral)
Description: Oral Self-administration
Study NCT03294460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (IV)
Description: IV Self-administration
Study NCT03294460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Ethanol)
Description: IV and Oral Self-administration
Study NCT04444921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT04444921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04444921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04444921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT04444921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03777878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 2 ampoules of TA in 100 ml saline by slow infusion
Study NCT03777878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to carbetocin
Description: placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
Study NCT03777878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Study NCT03171519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
Study NCT03171519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
Study NCT03171519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
Study NCT03811392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernioraphy/Caudal block
Description: 30 patients will receive a caudal block after induction of general anaesthesia
Study NCT03811392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernioraphy/Quadratus Lumborum block
Description: 30 patients will receive ultrasound guided quadrates lumborum block
Study NCT02841683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tabac Info Service
Description: A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
Study NCT02063867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Decolonization
Description: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Study NCT01285570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Intravenously (IV)
Description: 480 microg/kg daily (QD)
Study NCT01285570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Intravenously (IV)
Description: 160 microg/kg daily (QD)
Study NCT01285570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: Placebo
Study NCT00802126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy IVB + rf-PDT
Description: low-fluence photodynamic therapy combined with intravitreal bevacizumab
Study NCT00093496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00093496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00402428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin interferon alfa-2b
Description: 900 mcg or 1200mcg every two week for 48 weeks
Study NCT00402428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Description: 180 mcg once a week for 48 weeks
Study NCT00402428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,> 75kg)
Study NCT00402428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,> 75kg)
Study NCT04666103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative thermal ablation
Description: After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy.
Study NCT02975739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 (poly L lactic acid) microspheres
Description: Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
Study NCT01487174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD019
Description: KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
Study NCT01487174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
Study NCT03576196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Pain Neuroscience Education
Description: Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
Study NCT03576196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
Study NCT02358161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and nab paclitaxel
Description: DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
Study NCT02132455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
Study NCT03241680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Search of anal citology alterations
Description: All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE).
Study NCT02818023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib.